Biomarker testing, in plain language
Biomarker tests look at the genes and proteins in your cancer, and they can open the door to treatments made for your exact cancer. If all the letters and numbers feel overwhelming, you're not alone. Pick a test below to learn what it means for you and your family.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
Tissue vs. blood
Most tests use a piece of tumor tissue from a biopsy or surgery. Some can also use a blood sample (a 'liquid biopsy') that looks for tumor DNA floating in the blood. Blood tests are easier and faster, but they can miss a change that a tissue test would find, so a negative blood test is often followed by a tissue test.
By cancer type
Breast cancer
ER/PR (hormone receptors), HER2, BRCA1 and BRCA2, PIK3CA, PD-L1
Lung cancer
EGFR, ALK, ROS1, KRAS (including G12C), BRAF, MET, RET, NTRK, PD-L1
Prostate cancer
PSA (prostate-specific antigen), AR and PSMA, BRCA1 and BRCA2, HRD (homologous recombination deficiency), MSI-H / dMMR
Colorectal cancer
MSI-H / dMMR, KRAS (including G12C), BRAF, HER2, NTRK
Ovarian cancer
BRCA1 and BRCA2, HRD (homologous recombination deficiency), MSI-H / dMMR
Browse biomarker tests
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write
Sources
- NCI: Biomarker Testing for Cancer Treatment
- American Cancer Society: Biomarker Tests and Cancer Treatment
- FDA: List of Cleared or Approved Companion Diagnostic Devices
- Cleveland Clinic: Tumor Markers
- NCCN Guidelines for Patients: Invasive Breast Cancer, 2026
- NCCN Guidelines for Patients: Ductal Carcinoma in Situ (Stage 0 Breast Cancer), 2026
- NCCN Guidelines for Patients: Metastatic Breast Cancer, 2026
- NCCN Guidelines for Patients: Inflammatory Breast Cancer, 2026
- NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Early-Stage Prostate Cancer, 2026
- NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer, 2026
- NCCN Guidelines for Patients: Colon Cancer, 2026
- NCCN Guidelines for Patients: Rectal Cancer, 2026
- NCCN Guidelines for Patients: Ovarian Cancer, 2026